Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study

J Pediatr. 2004 Dec;145(6):856-7. doi: 10.1016/j.jpeds.2004.08.020.

Abstract

Thirteen children with difficult systemic onset juvenile rheumatoid arthritis were treated with thalidomide. At 6 months, 11 of the 13 were able to reduce their use of prednisone ( P < .002), with a concurrent improvement in erythrocyte sedimentation rate ( P < .0001) and an increase in hemoglobin level ( P < 0.005). Juvenile rheumatoid arthritis improvement scores >/=50% were obtained by 10 of the 13 children.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Juvenile / drug therapy*
  • Blood Sedimentation / drug effects
  • Child
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Thalidomide / therapeutic use*
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Thalidomide